Viyash Scientific Ltd. benchmarking: Perfomance to industry peers

Financial

	Viyash Scientific	Procter&Gamble Healt	Sanofi India
Operational Metrics
Pharmaceuticals
R&D as a % of Total Sales	0.0	n/a	0.0
Financials
5 yr Average ROE	-0.13 %	36.03 %	52.02 %
5yr average Equity Multiplier	2.16	1.79	4.62
5yr Average Asset Turnover Ratio	0.95	0.77	0.47
5yr Avg Net Profit Margin	0.03 %	19.19 %	24.38 %
Price to Book	11.04	14.48	10.75
P/E	213.56	29.24	22.39
5yr Avg Cash Conversion Cycle	49.09 Days	-155.74 Days	4.83 Days
Inventory Days	80.25 Days	36.01 Days	66.8 Days
Days Receivable	79.76 Days	40.92 Days	31.98 Days
Days Payable	114.46 Days	215.28 Days	63.37 Days
5yr Average Interest Coverage Ratio	1.93	500.05	906.11
5yr Avg ROCE	6.67 %	30.21 %	27.19 %
5yr Avg Operating Profit Margin	7.74 %	27.53 %	24.71 %
5 yr average Debt to Equity	0.53	0.0	0.0
5yr CAGR Net Profit	-25.52 %	4.02 %	31.63 %
5yr Average Return on Assets	0.05 %	15.5 %	11.5 %
Shareholdings
Promoter Holding	61.41 %	51.82 %	60.4 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	8.62 %	0.0	0.0
Change in Mutual Fund Holding (3 Yrs)	5.57 %	3.2 %	0.06 %

Business

	Viyash Scientific	Procter&Gamble Healt	Sanofi India
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0 Chemical Segment 0 Pharmaceutical Segment 0	Segment Break-Up Both 0 Companion animal 0 Pharmaceutical 100.0 Chemical Segment 0 Production animal 0	-
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0 Chemical Segment 0 Pharmaceutical Segment 0	Segment Break-Up Both 0 Companion animal 0 Pharmaceutical 100.0 Chemical Segment 0 Production animal 0	-
Product Wise Break-Up	Product Wise Break-Up Formulations 79.96 Active Pharmaceutical Ingredient (API) 19.73 Pharmaceuticals 0 Others 0.31	-	Product Wise Break-Up Active Pharmaceutical Ingredient (API) 0 Formulations 0 Pharmaceutical 100.0
Location Wise Break-Up	Location Wise Break-Up Europe 45.13 Asia Pacific 28.68 Rest of the World 26.19 Turkey 0 LATAM 0 EM 0 International 0 Domestic 0 Singapore 0 India 0	Location Wise Break-Up Rest of the World 0 India 0 Asia Pacific 0 Europe 0 International 6.81 Domestic 93.19 Singapore 0 LATAM 0 Turkey 0 EM 0	Location Wise Break-Up Rest of the World 0 India 79.71 Asia Pacific 0 Europe 0 International 0 Domestic 0 Singapore 20.29 LATAM 0 Turkey 0 EM 0
Customer Segment	Customer Segment Regulated market 67.0 Less regulated market 33.0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Antibiotic Injectables 33.0 Antibiotic Non-Injectables 15.0 Anthelmintics 11.0 Nutritional 0 Pain management 0 Vitamins 0 Anti Malarials 0 Neuro/CNS 0 Pain Mgmt 0 Hormones 0 Anti-Infectives 0 Respiratory 0 Anti-Neoplastics 0 Gastrointestinal 0 Anti-Diabetic 0 Derma 0 Cardiac 0 Gynaecology 0 Others 41.0	Therapeutic Area Break-Up Cardiac Science 17.0 Nutritional 0 Pain Management 1.0 Anti-Neoplastics 2.0 Anthelmintics 0 Anti Malarials 0 Neuro/CNS 0 Antibiotic Non-Injectables 0 Hormones 1.0 Anti - Diabetes 4.0 Gastro Intestinal 2.0 Pain management 0 Respiratory Systems 1.0 Derma 6.0 Gynecology 17.0 Vitamins / Minerals / Nutrients 48.0 Antibiotic Injectables 0 Anti-Infective 1.0	-
R&D Break-Up - Product Wise	R&D Break-Up - Product Wise Formulations 40.0 NiCad 29.0 Patent expiry opportunity 18.0 First generic 9.0 Incremental innovation 4.0	-	-
Dosage Form Break-Up	Dosage Form Break-Up Injectable 55.0 Powder/Premixes 26.0 Solid 6.0 Paste and others 0 Pour on/Spot on 0 Oral Solutions/Suspensions 0 Others 13.0	-	-
Asset Break-Up	Asset Break-Up Asia Pacific 43.23 Europe 34.35 Rest of the World 22.42 India 0	Asset Break-Up Europe 0 Rest of the World 0 India 100.0 Asia Pacific 0	-
Species Break-Up	Species Break-Up Multispecies 39.0 Ruminants 32.0 Poultry And Poultry Products 12.0 Companion 10.0 Swine 6.0 Others 1.0	-	-

Viyash Scientific Ltd.

Viyash Scientific Ltd.

Financial

Business

SIGN UP FOR FREE